원형 탈모증 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global alopecia areata market size is expected to reach USD 9.19 Billion in 2034 from USD 4.30 Billion in 2025, growing at a CAGR of 8.81% during 2026-2034.This market is growing as awareness of alopecia areata increases and patients seek more effective options for managing autoimmune-related hair loss. Greater recognition of the psychological and social effects associated with visible hair loss is encouraging patients to pursue diagnosis and treatment. Advances in dermatology are also supporting market development, particularly through targeted therapies designed to address underlying immune mechanisms. Improved access to specialist care, increasing clinical research, and stronger patient advocacy are further expanding treatment opportunities across developed and emerging healthcare markets.

Growth is being driven by the introduction of innovative therapies, expanding clinical evidence, and greater physician familiarity with advanced treatment approaches. Oral and targeted therapies are creating additional options for patients who may not respond adequately to conventional treatments. Pharmaceutical companies are also increasing investment in autoimmune and inflammatory disease pipelines, supporting product innovation. Improved diagnosis and greater awareness among primary care providers can help reduce treatment delays, while digital health platforms and patient communities are contributing to greater information availability and treatment consideration.

Future prospects remain favorable as research continues to identify new therapeutic targets and improve long-term disease management. Developers are expected to focus on treatments offering improved efficacy, safety, durability, and convenience. Expansion into underserved markets could provide additional opportunities as dermatology infrastructure and healthcare access improve. Personalized treatment strategies may also gain importance as understanding of disease heterogeneity develops. Competition is likely to increase as more therapies enter the market, encouraging innovation, broader treatment choices, and potentially improved accessibility for patients.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Patchy Alopecia Areata
• Alopecia Totalis
• Alopecia Universalis
• Diffuse Alopecia Areata
• Ophiasis Alopecia

By Diagnosis

• Trichoscopy
• Skin Biopsy
• Other Diagnoses

By Route of Administration

• Oral
• Topical
• Parenteral
• Other Routes of Administration

By End Users

• Hospitals
• Specialty Clinics

COMPANIES PROFILED

• Pfizer Inc., Eli Lilly and Company, Incyte Corporation, AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb, GlaxoSmithKline plc, Aclaris Therapeutics Inc., Almirall SA, Lupin Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Dr Reddys Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Arena Pharmaceuticals, AnaptysBio Inc., Viela Bio

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ALOPECIA AREATA MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Patchy Alopecia Areata Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Alopecia Totalis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Alopecia Universalis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Diffuse Alopecia Areata Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Ophiasis Alopecia Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ALOPECIA AREATA MARKET: BY DIAGNOSIS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Diagnosis
• 5.2. Trichoscopy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Skin Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Diagnoses Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ALOPECIA AREATA MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other Routes of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ALOPECIA AREATA MARKET: BY END USERS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Users
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ALOPECIA AREATA MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Diagnosis
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End Users
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Diagnosis
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End Users
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Diagnosis
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End Users
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Diagnosis
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End Users
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Diagnosis
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End Users
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ALOPECIA AREATA INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 Eli Lilly And Company
  • 10.2.3 Incyte Corporation
  • 10.2.4 AbbVie Inc
  • 10.2.5 Novartis AG
  • 10.2.6 Sanofi SA
  • 10.2.7 Bristol Myers Squibb
  • 10.2.8 GlaxoSmithKline Plc
  • 10.2.9 Aclaris Therapeutics Inc
  • 10.2.10 Almirall SA
  • 10.2.11 Lupin Ltd
  • 10.2.12 Sun Pharmaceutical Industries Ltd
  • 10.2.13 Cipla Ltd
  • 10.2.14 Glenmark Pharmaceuticals Ltd
  • 10.2.15 Dr Reddys Laboratories Ltd
  • 10.2.16 Teva Pharmaceutical Industries Ltd
  • 10.2.17 Janssen Pharmaceuticals
  • 10.2.18 Arena Pharmaceuticals
  • 10.2.19 AnaptysBio Inc
  • 10.2.20 Viela Bio